High-affinity ACP3 ligands for prostate cancer treatments
June 11, 2024
Philochem AG has discovered an ultra-high-affinity ACP3 ligand – OncoACP3 – isolated through the screening of DNA-encoded chemical libraries for the potential treatment of prostate cancer.